Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-30
DOI
10.1186/s10194-022-01417-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine
- (2022) Luigi Francesco Iannone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Immunogenicity of biologic therapies for migraine: a review of current evidence
- (2021) Joshua M. Cohen et al. JOURNAL OF HEADACHE AND PAIN
- Early outcomes of migraine after erenumab discontinuation: data from a real-life setting
- (2021) Eleonora De Matteis et al. NEUROLOGICAL SCIENCES
- Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study
- (2021) Andreas R Gantenbein et al. CEPHALALGIA
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
- (2021) Bianca Raffaelli et al. CEPHALALGIA
- Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
- (2019) Virginia L. Stauffer et al. HEADACHE
- Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
- (2019) Messoud Ashina et al. CEPHALALGIA
- Monoclonal antibodies for the prevention of migraine
- (2019) Bianca Raffaelli et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States
- (2017) J. Michael Woolley et al. HEADACHE
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
- (2013) Andrew M. Blumenfeld et al. HEADACHE
- Acquired lithium resistance revisited: Discontinuation-induced refractoriness versus tolerance
- (2011) Robert M. Post JOURNAL OF AFFECTIVE DISORDERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started